Cullinan Oncology launches new subsidiary focused on collagen-binding cytokine treatment

Max Gelman

Senior Editor

Cullinan Oncology operates as both a biotech and an investment fund, housing each of its assets in subsidiaries under one large umbrella. A little over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cullinan Oncology launches new subsidiary focused on collagen-binding cytokine treatment

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

GSK defiant against vaccine challenges, will prioritize other growth areas

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

We’re about to find out which RFK Jr. will show up at HHS

Cul­li­nan On­col­o­gy launch­es new sub­sidiary fo­cused on col­la­gen-bind­ing cy­tokine treat­ment

Senior Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Cullinan Oncology launches new subsidiary focused on collagen-binding cytokine treatment